List view / Grid view
This application note by ForteBio explores antibody fragment molecule (Fab) for process development and quality control.
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
Glycosylation is one of the most important post-translational modifications when developing new biologics. It has a considerable impact on product performance and variability and is therefore a critical quality attribute (CQA), influencing product safety and efficacy.
Scientists at Celgene Corporation developed a screening process incorporating the Octet® HTX system to identify pools and clones with higher concentrations of bispecific antibodies. Higher throughput was achieved from the multiple simultaneous measures possible on the Octet system and rapid assay times, such as binding optimisation in only 10 minutes.…
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
Cell line development typically includes the screening of thousands of clones to identify the few that are stable, grow as expected and produce high yields of the bioproduct.
